Article
Prognostic significance of PIK3CA mutation in stage IIB to IVA cervical cancers treated by concurrent chemoradiotherapy with weekly cisplatin.
Medicine - 1 Aug 2018
Lachkar Bouchra, Minaguchi Takeo, Akiyama Azusa, Liu Shuling, Zhang Shuang, Xu Chenyang, Shikama Ayumi, Tasaka Nobutaka, Sakurai Manabu, Nakao Sari, Ochi Hiroyuki, Yoshikawa Hiroyuki, Satoh Toyomi
Abstract excerpt
The standard treatment for locally advanced cervical cancer is cisplatin-based concurrent chemoradiotherapy (CCRT). Although the activated PI3-kinase/Akt pathway is known to be involved in both cisplatin-resistance and radioresistance, to date, only a few studies have reported significant associations between PIK3CA gene mutational status and outcome by CCRT in the disease. The aim of this study was to clarify...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.